Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Non-Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 14.9% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 14.9% year-over-year, with the annual reading at $2.4 million for FY2025, 14.9% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.4 million at Century Therapeutics, up from $2.3 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.8 million in Q3 2024, with the low at $526000.0 in Q1 2025.
  • Average Other Non-Current Assets over 4 years is $1.5 million, with a median of $1.4 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets soared 412.38% in 2024, then crashed 81.02% in 2025.
  • Over 4 years, Other Non-Current Assets stood at $1.3 million in 2022, then plummeted by 57.06% to $541000.0 in 2023, then skyrocketed by 412.38% to $2.8 million in 2024, then dropped by 14.9% to $2.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.4 million, $2.3 million, and $538000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.